Achillion data shows promise of shorter-duration hep C treatment

December 22, 2014 5:16 PM

14 0

(Reuters) - Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.

The company said on Monday it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.

Read more

To category page